Search

Biogen Inc

Suletud

SektorTervishoid

209.54 -0.26

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

208.04

Max

215.29

Põhinäitajad

By Trading Economics

Sissetulek

-639M

-320M

Müük

258M

2.7B

P/E

Sektori keskmine

36.922

57.002

Aktsiakasum

3.6

Kasumimarginaal

-11.678

Töötajad

7,500

EBITDA

-475M

78M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+12.02% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

29. okt 2026

Turustatistika

By TradingEconomics

Turukapital

754M

31B

Eelmine avamishind

209.8

Eelmine sulgemishind

209.54

Uudiste sentiment

By Acuity

46%

54%

161 / 340 Pingereas Healthcare

Biogen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. aug 2026, 20:06 UTC

News

Wolfe Research upgraded Biogen to Outperform, raising its price target to $300, citing a promising late-stage pipeline and recent acquisition of Apellis Pharmaceuticals.

12. aug 2026, 23:01 UTC

Biogen shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

11. aug 2026, 23:46 UTC

Biogen Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement amid broader market focus on economic indicators.

10. aug 2026, 19:36 UTC

Social Media

Biogen Inc has completed its $1 billion acquisition of RayThera. Shares are trading lower despite the strategic development and potential pipeline enhancement.

7. aug 2026, 23:16 UTC

Social Media

Biogen Inc completed the acquisition of RayThera, valued at up to $1 billion, but shares are lower in after-market trading.

6. aug 2026, 23:11 UTC

News

Biogen Inc. has completed its acquisition of RayThera Inc., enhancing its immunology portfolio. Shares are trading lower in after-market hours following a recent decline.

5. aug 2026, 19:26 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Despite strong results, shares are trading lower amid broader market declines.

4. aug 2026, 20:02 UTC

News

Mizuho raised its price target on Biogen Inc. to $241, contributing to the stock's upward movement during Tuesday's session.

3. aug 2026, 23:06 UTC

Biogen Inc. shares are trading higher in after-market hours, supported by stronger-than-expected manufacturing data and positive broader market sentiment.

31. juuli 2026, 21:01 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Shares are higher in after-market trading following the positive results and raised EPS guidance.

30. juuli 2026, 19:39 UTC

Biogen Inc shares are lower in Thursday's session, reaching a low of approximately -2.86% earlier. No specific news was identified to explain the decline.

29. juuli 2026, 22:02 UTC

Biogen Inc shares are higher in after-market hours, maintaining a steady upward trajectory since Wednesday's close and staying above the 20-day moving average.

28. juuli 2026, 22:01 UTC

Biogen Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains above its 20-day moving average.

27. juuli 2026, 18:56 UTC

Biogen Inc. shares are lower today amid routine trading fluctuations. Broader market declines are influenced by falling oil prices ahead of the Federal Reserve meeting.

24. juuli 2026, 18:26 UTC

Biogen Inc. shares are higher today, continuing an upward trend since Thursday. The stock's movement appears independent of recent oil price volatility.

22. juuli 2026, 22:01 UTC

Biogen Inc shares are trading higher in after-market hours, reflecting an increase since Wednesday's close amid broader market volatility and rising crude oil prices.

21. juuli 2026, 19:46 UTC

News

BIIB trading higher after Guggenheim raised price target to $280.

20. juuli 2026, 22:06 UTC

Biogen Inc. shares rose slightly in after-market hours, despite broader market pressure from a decline in the Conference Board's leading economic index.

17. juuli 2026, 20:02 UTC

Biogen Inc's shares are lower today, continuing a downward trend since Thursday. The broader market reflects a general decline amid notable sell-offs in technology stocks.

16. juuli 2026, 19:02 UTC

News

Biogen partners with Synapticure to launch a virtual ataxia care program. Shares are higher today, reflecting positive sentiment since Wednesday's close.

15. juuli 2026, 23:36 UTC

Biogen Inc. shares declined in after-market trading, reflecting ongoing weakness amid broader market caution related to geopolitical tensions involving the U.S. and Iran.

14. juuli 2026, 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

13. juuli 2026, 23:06 UTC

Social Media
News

Biogen received FDA approval for LEQEMBI IQLIK, a subcutaneous Alzheimer's treatment, boosting shares modestly higher in after-market trading.

10. juuli 2026, 21:01 UTC

Biogen Inc shares declined in after-market trading, reversing an initial uptick and nearing the lower end of their one-month trading range. No specific news was identified.

9. juuli 2026, 23:46 UTC

Biogen Inc shares are trading lower in after-market hours, continuing a trend of five consecutive daily declines without any specific news to explain the movement.

8. juuli 2026, 23:56 UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

7. juuli 2026, 23:31 UTC

Biogen Inc shares are higher in after-market trading following Tuesday's close, amid broader market volatility but stable performance above its 20-day moving average.

6. juuli 2026, 23:56 UTC

Biogen Inc. shares are higher in after-market trading, reflecting a slight upward movement since Monday's close and settling near the upper end of their one-month range.

2. juuli 2026, 22:16 UTC

Biogen Inc shares are lower in after-market hours, reflecting a decline since Thursday's close amid mixed market sentiment and a weaker jobs report.

1. juuli 2026, 20:07 UTC

Event

Biogen Inc. shares are lower as broader market sell-offs raise volatility. Barclays notes vulnerabilities in U.S. equity markets affecting investor sentiment.

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

12.02% tõus

12 kuu keskmine prognoos

Keskmine 235.96 USD  12.02%

Kõrge 300 USD

Madal 157 USD

Põhineb 29 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

29 ratings

19

Osta

9

Hoia

1

Müü

Sentiment

By Acuity

161 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat